amisulpride / Generic mfg. - LARVOL DELTA

Pharmacological rescue of social deficits in rats featuring Disrupted-in-Schizophrenia-1 (DISC1) protein aggregation. (PubMed, Schizophrenia (Heidelb)) - "Here, we tested whether continuous administration of atypical antipsychotics amisulpride or clozapine would rescue social deficits in tgDISC1 rats. Together, these findings demonstrate that amisulpride, a selective D2/D3 receptor antagonist, rescues social adaptability deficits linked to aberrant DISC1 signaling. The results also highlight the success of our precision psychiatry approach: the biological definition of a subset of schizophrenia by identifying DISC1 protein aggregates, the generation of a corresponding animal model and a successful pharmacotherapy of a clinically relevant phenotype."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Enhancing Recovery in Early Schizophrenia (clinicaltrials.gov) - P2 | N=180 | Active, not recruiting | Sponsor: Central Institute of Mental Health, Mannheim | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2026 ➔ Dec 2027 | Trial primary completion date: Jun 2026 ➔ Dec 2027

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Box-Behnken optimized salting-out assisted liquid-liquid extraction coupled with LC-MS/MS for sustainable amisulpride quantification in human plasma. (PubMed, J Chromatogr A) - "Following optimization, chromatographic separation was achieved using a C18 column with isocratic elution (acetonitrile:water with 0.1% formic acid, 70:30 v/v) and 4-minute analysis time, with multiple reaction monitoring employing transitions m/z370.1→242.1 for amisulpride and m/z376.2→165.1 for haloperidol internal standard. Clinical application in healthy volunteers (n = 5) following 200 mg oral amisulpride administration successfully characterized key pharmacokinetic parameters including Cmax (506 ng/mL), tmax (3.8 h), and t1/2 (13.3 h) over 48 h. Finally, multi-metric sustainability assessment using CaFRI (75/100), BAGI (77.5/100), and RGB12 (83.1/100 whiteness) frameworks confirmed achievement of white analytical chemistry through balanced analytical performance, environmental friendliness, and practical implementation feasibility. The method offers significant advantages including minimal waste generation, reduced solvent consumption, and enhanced throughput while..."

Journal

Rethinking Amisulpride: Could N-Methylation Result in a New and Even Better Antipsychotic? (PubMed, J Clin Psychiatry) - No abstract available

Journal • CNS Disorders

Levels of and changes in psychosis symptoms and clinical insight: Exploring the impact of differential antipsychotic mechanisms. (PubMed, Psychiatry Res) - "Symptom reduction is associated with improved insight, with early changes in positive symptoms exerting the fastest effect. Despite symptom improvement, aripiprazole PDA treatment was linked to less insight gain than DA treatment. These preliminary findings warrant further study."

Journal • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Overall and Sex-Based Risk Factors for Hyperprolactinemia in Patients With Schizophrenia: A Retrospective Cohort Study. (PubMed, Curr Neuropharmacol) - "Multiple pharmacological and non-pharmacological factors contribute to HPRL in patients with schizophrenia, with notable sex-specific differences. The potential role of HPRL in breast cancer development among female patients requires further investigation."

Journal • Retrospective data • Breast Cancer • CNS Disorders • Oncology • Psychiatry • Schizophrenia • Solid Tumor

Exploring wanting and liking during positive human-animal interactions. (PubMed, Psychopharmacology (Berl)) - "These altered reward-related behaviours along with the absence of side-effects are the first indicators for the safe and effective use of amisulpride and naloxone to non-invasively study reward mechanisms in domesticated animals."

Journal

The value of repetitive transcranial magnetic stimulation combined with amisulpride enhancement olanzapine therapy for resistant treatment-refractory schizophrenia. (PubMed, Front Psychiatry) - "rTMS is a widely used treatment method for schizophrenia. This study found that rTMS combined with amisulpride enhanced olanzapine treatment for TRS can significantly improve patients' symptoms, cognitive function, and quality of life, with tolerability and safety."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Dose-dependent pharmacological mechanisms within the Neuroscience-based Nomenclature: a new concept to facilitate neuroscience-based prescribing. (PubMed, Lancet Psychiatry) - "Using the Neuroscience-based Nomenclature (NbN) framework, which classifies drugs by pharmacology and modes of action, we identified ten agents demonstrating DDDP in a comprehensive expert-based consensus process: amisulpride, amitriptyline, aripiprazole, brexpiprazole, cariprazine, doxepin, mirtazapine, quetiapine, risperidone, and trazodone...Understanding these differences supports more rational prescribing (eg, increasing dopamine partial agonist doses beyond the optimal range might reduce efficacy). DDDP, within the NbN framework, offers a neuroscience-based approach to more precise psychopharmacology."

Journal • Review • NBN

Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings (clinicaltrials.gov) - P1 | N=100 | Not yet recruiting | Sponsor: Stanford University

New P1 trial

Exploring brain structural effects of dopaminergic antagonism and partial agonism in antipsychotic-naïve patients with first-episode psychosis using normative modeling. (PubMed, Psychiatry Clin Neurosci) - "Both partial D2R agonism and D2R antagonism appear linked to striatal volume increases; however, changes appear transient. Conversely, frontal thinning occurs over time and appears less closely linked to antipsychotic treatment. Interpreting structural brain changes in patients with psychosis require consideration of short-term pharmacological effects as well as factors related to illness progression."

Journal • CNS Disorders • Psychiatry • Schizophrenia • DRD2

Medication Use Evaluation of Amisulpride for the Management of Postoperative Nausea and Vomiting (ASHP 2025) - No abstract available

Retrospective Evaluation of Amisulpride Use for the Management of Postoperative Nausea and Vomiting (PONV) (ASHP 2025) - No abstract available

Retrospective data

Comment on "Immunomodulatory effects of amisulpride on mammalian macrophages". (PubMed, Ir J Med Sci) - No abstract available

Journal

Confirmatory factor analysis of competing PANSS negative symptom models: data from OPTiMiSE first-episode schizophrenia study. (PubMed, BJPsych Open) - "A nine-item PANSS model incorporating social amotivation and expressive deficit dimensions appeared to best reflect the underlying structure of negative symptoms in our sample."

Journal • CNS Disorders • Depression • Psychiatry • Schizophrenia

Magnetic Seizure Therapy for Psychotic Disorders (clinicaltrials.gov) - P=N/A | N=50 | Recruiting | Sponsor: Shanghai Jiao Tong University School of Medicine | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Epilepsy • Psychiatry

Immunomodulatory effects of amisulpride on mammalian macrophages. (PubMed, Ir J Med Sci) - "Amisulpride exhibits immunomodulatory activity under inflammatory conditions. These findings suggest a potential anti-inflammatory mechanism that warrants further investigation."

Journal • CNS Disorders • Immunology • Inflammation • Mental Retardation • Psychiatry • CSF2 • IL6 • TNFA

Molecular and topographic mapping of antipsychotic effects: a meta-analysis of postsynaptic density proteins in animal models with translational implications. (PubMed, Mol Psychiatry) - "Haloperidol, amisulpride, and aripiprazole significantly increased PSD protein expression in the striatum. Acute olanzapine increased PSD molecules levels in striatal regions, reducing Arc expression in frontal cortex (SMD [95%CIs]=-2.15 [-2.7;-1.61], p < 0.0001); chronic treatment had opposite effects. Clozapine increased Homer1a levels in dorsal (1.13 [0.41;1.86], p = 0.002) and ventral striatum (1.48 [0.72;2.24], p = 0.0001), and cingulate cortex (2.12 [1.12;3.12], p < 0.0001), as well as increased NMDAR subunits levels in frontal cortex."

Journal • Preclinical • Retrospective data • Review • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia • DRD2

QT interval prolongation in acute antipsychotic poisoning: systematic review and recommendations. (PubMed, Clin Toxicol (Phila)) - "Individual medication recommendations were made for amisulpride (15 articles), thioridazine (11 articles), ziprasidone (eight articles) and quetiapine (13 articles), whilst consensus statements based on limited data were made for acute ingestions of clozapine, haloperidol, iloperidone, pimozide, pipamperone, olanzapine and risperidone (14 articles in total). The QT Interval Prolongation in Clinical Toxicology Workgroup suggests the same approach for patients with overdoses of haloperidol, iloperidone, pipamperone and pimozide. The risk of torsade de pointes is likely overstated for acute antipsychotic medication overdose as a general class group, and concern should rather focus on a few specific medications."

Journal • CNS Disorders

Reward learning impairment from punishment-associated exploration depends on dopaminergic signaling (Neuroscience 2025) - "We found that pharmacological blockade of dopamine D2/3 receptor with amisulpride eliminated both the impairment in reward learning and the accompanying increase in exploration. These findings demonstrate that reward learning can be disrupted by punishment-driven exploration in a dopamine-dependent manner, offering a mechanistic account of how the brain resolves competing value signals and insights into dopamine-related learning disturbances in neuropsychiatric conditions."

CNS Disorders • Cognitive Disorders • Psychiatry

Three-week effect of amisulpride, aripiprazole, and olanzapine on gene expression in peripheral blood in individuals with schizophrenia spectrum disorders (ECNP 2025) - "The gene expression profiles suggest that previous exposure to antipsychotics primes some individuals for an inflammation-like response when changing to a different antipsychotic drug. No conflict of interest"

Clinical • CNS Disorders • Psychiatry • Schizophrenia • CTSG • ELANE • MPO • SELENBP1 • SLPI • SPTB • TMC2

Psychodermatology in early psychosis: optimising the mind-skin link (ECNP 2025) - "Participants were aged 18–40, met DSM-IV criteria for schizophrenia, schizophreniform, or schizoaffective disorder, had a duration of psychosis <24 months, minimal or no prior antipsychotic exposure (≤2 weeks at baseline), and all received open-label amisulpride treatment for 4 weeks [5]... Our findings suggest that DS may represent a marker of illness severity and poor short-term outcomes in the early stages of psychosis, potentially identifying a subgroup of patients with a poorer clinical prognosis who may benefit from early tailored interventions. Further research is warranted to explore the potential role of DS as early clinical predictors in psychosis."

CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia • Schizophreniform Disorder

Comparative evaluation of the impact of clozapine and other antipsychotics on insight in schizophrenia (ECNP 2025) - "Among them, 20 patients were prescribed Clozapine, and the remaining 20 patients were prescribed other antipsychotic medications (such as Risperidone, Olanzapine, or Amisulpride). However, the higher risk of certain side effects associated with clozapine should also be taken into consideration when making treatment decisions. Further research and larger-scale studies are necessary to confirm these findings and explore the long-term effects and safety profiles of these medications."

CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

Psychosis-mimicking Niemann-Pick Type C case with neuropsychiatric signs underscores importance of early diagnosis in atypical presentations (ECNP 2025) - "Initially diagnosed with generalized anxiety disorder, she was treated with sertraline and risperidone, showing partial improvement. However, psychotic symptoms persisted, leading to an increase in risperidone dosage and the addition of quetiapine, with minimal effect.The patient later developed urinary incontinence, which was attributed to risperidone after ruling out organic causes. Risperidone was replaced with amisulpride, resulting in improvement of both the psychotic symptoms and the incontinence...NPC should be considered in the differential diagnosis of psychosis with an atypical course and neurological features. Genetic testing should be considered in selected cases to facilitate early diagnosis and appropriate management."

Clinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry • Schizophrenia • NPC1 • NPC2

Atypical neuroleptic malignant syndrome due to antipsychotic discontinuation in a 38-year-old patient with schizophrenia and ankylosing spondylitis following ileus (ECNP 2025) - "Diagnosed with ileus, his antipsychotic medications — clozapine (300 mg/day), risperidone (2 mg/day), and quetiapine (100 mg/day)—were discontinued...Previous treatments included olanzapine, haloperidol, amisulpride, clozapine and paliperidone...Infectious disease specialists started antibiotics and rheumatology initiated adalimumab (40 mg/2 weeks)...Bromocriptine (15 mg/day), amantadine (300 mg/day) and diazepam (10 mg/day) were introduced, followed by careful titration of quetiapine to 250 mg/day... NMS is clinically characterized by hyperthermia, muscular rigidity, altered consciousness, autonomic dysfunction, elevated serum creatine phosphokinase levels and leukocytosis. Risk factors include high-potency antipsychotic use, young age, male sex, movement disorders, and comorbid neurological or medical conditions. Rapid dose escalation, abrupt discontinuation, anticholinergic withdrawal, dehydration, and a previous history of NMS further increase the risk."

Clinical • CNS Disorders • Mental Retardation • Movement Disorders • Psychiatry • Schizophrenia • Sleep Disorder